Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to